Skip to main content

Table 1 Reported progression-free and overall survival for endometrial cancer patients treated with “sandwich” chemotherapy and radiation therapy

From: Long term follow-up of a phase II trial of multimodal therapy given in a “sandwich” method for stage III, IV, and recurrent endometrial cancer

  Overall survival Progression-free survival
Lead Author, Year N UPSC/clear cell/mixed Deaths 3-years OS Median follow-up (months) N Recur, progression or death (N) 3-years PFS
Gehrig, 2004 [25] 9 100 %/0 %/0 % 0 100 % 38 N/A 1 N/A
aLupe, 2007 [26] 33 33 %/9 %/15 % 13 55 % (2-years) 21 33 14 55 % (2-years)
Secord, 2007 [27] 51 N/A 5 91 % 36 51 13 69 %
aFields, 2008 [28] 30 100 %/0 %/0 % 10 52 % N/A 29 12 54 %
aLupe, 2009 [16] 43 35 %/7 %/14 % 14 68 % 30 41 35 53 %
Secord, 2009 [29] 45 13 %/4 %/29 % 7 88 % 36 45 11 69 %
Geller, 2010 [17] 23 52 %/4 %/0 % 3 88 % 44 23 5 80 %
aGeller, 2011 [4] 41 9 %/NA/2 % 7 90 % 28 39 11 71 %
Abaid, 2012 [5] 32 13 %/9 %/9 % 3 N/A 19 8 8 84 %
aEinstein, 2012 [6]   100 %/0 %0 %   84 % (early stage); 50 % (advanced stage) 9 20 20 N/A
Dogan, 2013 [7] 11 18 %/18 %/0 % 0 N/A 18 1 5 N/A
Lan, 2013 [30] 35 N/A 4 82 % 36 35 9 62 %
aGeller, 2011 - updated 41 9 %/NA/2 % 15 75 % 60 39 15 71 %
  1. UPSC uterine papillary serous carcinoma, PFS progression-free survival
  2. aProspective study